Kodiak Sciences/$KOD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Kodiak Sciences

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.

Ticker

$KOD
Primary listing

Industry

Biotechnology

Employees

113
Website

Kodiak Sciences Metrics

BasicAdvanced
$434M
-
-$3.62
2.43
-

What the Analysts think about Kodiak Sciences

Analyst ratings (Buy, Hold, Sell) for Kodiak Sciences stock.

Bulls say / Bears say

Kodiak ended Q1 2025 with $138.9 million in cash and cash equivalents, providing a runway into 2026 and supporting ongoing Phase 3 trials.
Upon successful topline data from Phase 3 GLOW2 and DAYBREAK, Kodiak plans to file a single BLA in 2026 for three indications, potentially accelerating market entry and revenue.
Early Phase 1b APEX data presented in January 2025 demonstrated strong treatment responses in MESI patients with KSI-101, highlighting the promise of its inflammation-targeting program.
In Q1 2025, Kodiak reported a net loss of $57.5 million or $1.09 per share, with R&D expenses up 45.8% year-over-year, underscoring high cash burn.
HC Wainwright cut its Q2 2025 EPS forecast to ($1.09) from ($0.99), reflecting a dim near-term profitability outlook and cautious analyst sentiment.
Shares have plunged approximately 60% year-to-date, indicating significant investor skepticism around clinical success and funding risk.
Data summarised monthly by Lightyear AI. Last updated on 22 Jul 2025.

Kodiak Sciences Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Kodiak Sciences Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KOD

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs